The pharmaceutical company Darnitsa, within the framework of the philosophy of continuous improvement, moved to the second stage of implementation of projects to improve production processes. Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, said that when developing projects to modernize production, the pharmaceutical concern primarily focuses on operations and processes. In 2020, UAH 180.5 million of capital investments were allocated to modernize production and ensure compliance with international standards, maintain a high quality with minimal resource expenditures and reduce the term to create products. A special attention is also paid to the organization of supplies and ensuring the demand for medicines, regardless of the turbulence of the external environment.
The Darnitsa production development strategy is calculated until 2030. In addition to systemic investments in modernization, it includes a policy of continuous improvement of processes, as well as the involvement of all employees to maximize focus on the interests and needs of consumers.
In particular, now the company uses the SMED (Single-Minute Exchange of Dies) tools to improve the efficiency of production processes. In 2020, 8 such projects were completed. The average reduction in time spent on operations in production units where re-installation projects were implemented was 24.4%. Within 6 months of 2021, 5 projects were completed, which reduced the duration of changeovers by an average of 32.2%. Since the beginning of the SMED program, the total changeover performance time for the company has decreased by 1.7%.
Also, an extensive training was carried out for employees concerning the implementation of Kaizen projects. At the moment, the implementation of the projects aimed at improving quality management processes and increasing operational efficiency and resource saving is being completed.
Darnitsa is the largest pharmaceutical manufacturer in Ukraine, certified according to the EU GMP. During 2010-2020, the company invested UAH 1.218 billion in the modernization and development of production. Due to the focus on development and the use of innovative technologies and equipment, Darnitsa guarantees that the production of medicines is carried out under controlled conditions in compliance with the GMP requirements.